Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Holding BIIB?
Track your performance easily
BIIB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$145.07 - $268.30
Previous Close$146.47
Volume5.78M
Average Volume (3M)1.53M
Market Cap
$21.34B
Enterprise Value$27.99B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$6.65B
Price to Earnings (P/E)13.2
Beta0.77
Next Earnings
Jan 30, 2025EPS Estimate
$3.42Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)11.07
Shares Outstanding145,719,340
10 Day Avg. Volume1,389,469
30 Day Avg. Volume1,525,788
Standard Deviation0.09
R-Squared0.00219
Alpha-0.00553
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)1.30
Price to Sales (P/S)2.22
Price to Cash Flow (P/CF)5.70
P/FCF Ratio6.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit3.83
Enterprise Value/Ebitda8.95
Forecast
1Y Price Target
$238.90Price Target Upside63.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
Biogen News
PremiumMarket News
VOO ETF Update, 12/20/2024 
PremiumMarket News
SPY ETF Update, 12/19/2024 
PremiumMarket News
QQQ ETF Update, 12/18/2024 
PremiumMarket News
VOO ETF Update, 12/17/2024 
PremiumMarket News
SPY ETF Update, 12/16/2024 Bulls Say, Bears Say
Bulls Say
Market ExpansionBiogen partner Eisai's request for the EMA's CHMP to reexamine the MAA for lecanemab in amyloid-positive early Alzheimer's disease has paid off with a positive recommendation, preserving the majority of the addressable patient population - approximately 85-90%.
Product DifferentiationFelzartamab is expected to be a differentiated product in IgAN and a solid early entrant in pMN and AMR, with the potential for over $5 billion in peak sales opportunities.
Regulatory ApprovalThe EMA announced a positive CHMP recommendation to approve Leqembi in the EU, overturning the negative opinion first issued.
Bears Say
Pipeline DevelopmentBiogen's pipeline remains underdeveloped following recent program cost cuts, with limited impactful catalysts expected in the near future.
Revenue GrowthLeqembi revenue growth is expected to be slower than initially anticipated, increasing reliance on other parts of the business.
Royalty ImpactThe Ocrevus royalty is expected to have a significant reduction in 2030, impacting earnings potential significantly.
---
Ownership Overview
0.14% Insiders
35.23% Mutual Funds
24.55% Other Institutional Investors
10.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $145.07 and its highest was $268.30 in the past 12 months.
What is Biogen’s market cap?
Currently, no data Available
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Jan 30, 2025 which is in 38 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Oct 30, 2024. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $3.772 by $0.308.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.225 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is $3.42.
How many shares outstanding does Biogen have?
Biogen has 145,719,350 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $4.08 in its last earnings report, beating expectations of $3.772. Following the earnings report the stock price went down -1.248%.
Which hedge fund is a major shareholder of Biogen?
Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 3B.
---
Biogen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$238.90 (63.11% Upside)
$238.90 (63.11% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 126.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.97%
12-Months-Change
Fundamentals
Return on Equity
10.47%
Trailing 12-Months
Asset Growth
0.43%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
BIIB Company Deck
---
BIIB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Biogen's earnings call highlighted significant progress in new product launches and a promising late-stage pipeline, resulting in raised financial guidance for the year. However, challenges persist in core revenue streams like MS and SPINRAZA, with infrastructure issues impacting LEQEMBI's U.S. performance.Read More>---
BIIB Revenue Breakdown
73.68% Product revenue
17.18% Revenue from anti-CD20 therapeutic programs
9.14% Other
---
BIIB Stock 12 Month Forecast
Average Price Target
$238.90
▲(63.11% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
1 Year Success Rate
11/39 ratings generated profit
1 Year Average Return
-7.20%
reiterated a buy rating 4 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 28.21% of your transactions generating a profit, with an average return of -7.20% per trade.
---